Inhibition of SRC-3 As a Potential Therapeutic Strategy for Aggressive Mantle Cell Lymphoma

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2024 Apr 29

PMID 38683834

Authors

Imani Bijou

Yang Liu

Dong Lu

Jianwei Chen

Shelby Sloan

Lapo Alinari

David M Lonard

Bert W OMalley

Michael Wang

Jin Wang

Affiliations

Soon will be listed here.

Abstract

Mantle cell lymphoma (MCL) has a poor prognosis and high relapse rates despite current therapies, necessitating novel treatment regimens. Inhibition of SRC-3 show effectiveness in vivo and in vitro in other B cell lymphomas. Additionally, previous studies have shown that SRC-3 is highly expressed in the lymph nodes of B cell non-Hodgkin's lymphoma patients, suggesting SRC-3 may play a role in the progression of B cell lymphoma. This study aimed to investigate novel SRC-3 inhibitors, SI-10 and SI-12, in mantle cell lymphoma. The cytotoxic effects of SI-10 and SI-12 were evaluated in vitro and demonstrated dose-dependent cytotoxicity in a panel of MCL cell lines. The in vivo efficacy of SI-10 was confirmed in two ibrutinib-resistant models: an immunocompetent disseminated A20 mouse model of B-cell lymphoma and a human PDX model of MCL. Notably, SI-10 treatment also resulted in a significant extension of survival in vivo with low toxicity in both ibrutinib-resistant murine models. We have investigated SI-10 as a novel anti-lymphoma compound via the inhibition of SRC-3 activity. These findings indicate that targeting SRC-3 should be investigated in combination with current clinical therapeutics as a novel strategy to expand the therapeutic index and to improve lymphoma outcomes.

References

Wu H, Wang J, Zhang X, Yang H, Wang Y, Sun P . Survival Trends in Patients Under Age 65 Years With Mantle Cell Lymphoma, 1995-2016: A SEER-Based Analysis. Front Oncol. 2020; 10:588314. PMC: 7606943. DOI: 10.3389/fonc.2020.588314. View

Mc Ilroy M, Fleming F, Buggy Y, Hill A, Young L . Tamoxifen-induced ER-alpha-SRC-3 interaction in HER2 positive human breast cancer; a possible mechanism for ER isoform specific recurrence. Endocr Relat Cancer. 2006; 13(4):1135-45. DOI: 10.1677/erc.1.01222. View

Song Y, Zhou K, Zou D, Zhou J, Hu J, Yang H . Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022; 139(21):3148-3158. PMC: 9136878. DOI: 10.1182/blood.2021014162. View

Elpek K, Lacelle C, Singh N, Yolcu E, Shirwan H . CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model. J Immunol. 2007; 178(11):6840-8. DOI: 10.4049/jimmunol.178.11.6840. View

Qin Y, Meng L, Hu C, Duan W, Zuo Z, Lin L . Gambogic acid inhibits the catalytic activity of human topoisomerase IIalpha by binding to its ATPase domain. Mol Cancer Ther. 2007; 6(9):2429-40. DOI: 10.1158/1535-7163.MCT-07-0147. View

Passineau M, Siegal G, Everts M, Pereboev A, Jhala D, Wang M . The natural history of a novel, systemic, disseminated model of syngeneic mouse B-cell lymphoma. Leuk Lymphoma. 2005; 46(11):1627-1638. DOI: 10.1080/10428190500221454x. View

Lahusen T, Fereshteh M, Oh A, Wellstein A, Riegel A . Epidermal growth factor receptor tyrosine phosphorylation and signaling controlled by a nuclear receptor coactivator, amplified in breast cancer 1. Cancer Res. 2007; 67(15):7256-65. PMC: 3656436. DOI: 10.1158/0008-5472.CAN-07-1013. View

Saleh K, Cheminant M, Chiron D, Burroni B, Ribrag V, Sarkozy C . Tumor Microenvironment and Immunotherapy-Based Approaches in Mantle Cell Lymphoma. Cancers (Basel). 2022; 14(13). PMC: 9265015. DOI: 10.3390/cancers14133229. View

Dasgupta S, Lonard D, OMalley B . Nuclear receptor coactivators: master regulators of human health and disease. Annu Rev Med. 2013; 65:279-92. PMC: 4327818. DOI: 10.1146/annurev-med-051812-145316. View

10.

Kumar S, Das S, Rachagani S, Kaur S, Joshi S, Johansson S . NCOA3-mediated upregulation of mucin expression via transcriptional and post-translational changes during the development of pancreatic cancer. Oncogene. 2014; 34(37):4879-89. PMC: 4476953. DOI: 10.1038/onc.2014.409. View

11.

Long W, Foulds C, Liu J, Ding C, Lonard D, Solis L . ERK3 signals through SRC-3 coactivator to promote human lung cancer cell invasion. J Clin Invest. 2012; 122(5):1869-80. PMC: 3336992. DOI: 10.1172/JCI61492. View

12.

Song X, Chen J, Zhao M, Zhang C, Yu Y, Lonard D . Development of potent small-molecule inhibitors to drug the undruggable steroid receptor coactivator-3. Proc Natl Acad Sci U S A. 2016; 113(18):4970-5. PMC: 4983835. DOI: 10.1073/pnas.1604274113. View

13.

Honigberg L, Smith A, Sirisawad M, Verner E, Loury D, Chang B . The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A. 2010; 107(29):13075-80. PMC: 2919935. DOI: 10.1073/pnas.1004594107. View

14.

Zhou H, Yan J, Luo W, Ayala G, Lin S, Erdem H . SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res. 2005; 65(17):7976-83. DOI: 10.1158/0008-5472.CAN-04-4076. View

15.

Chen J, Wang H, Jia L, He J, Li Y, Liu H . Bufalin targets the SRC-3/MIF pathway in chemoresistant cells to regulate M2 macrophage polarization in colorectal cancer. Cancer Lett. 2021; 513:63-74. DOI: 10.1016/j.canlet.2021.05.008. View

16.

Zhai D, Jin C, Shiau C, Kitada S, Satterthwait A, Reed J . Gambogic acid is an antagonist of antiapoptotic Bcl-2 family proteins. Mol Cancer Ther. 2008; 7(6):1639-46. PMC: 2614397. DOI: 10.1158/1535-7163.MCT-07-2373. View

17.

Dasgupta S, Rajapakshe K, Zhu B, Nikolai B, Yi P, Putluri N . Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer. Nature. 2018; 556(7700):249-254. PMC: 5895503. DOI: 10.1038/s41586-018-0018-1. View

18.

Li L, Nie L, Jordan A, Cai Q, Liu Y, Li Y . Targeting glutaminase is therapeutically effective in ibrutinib-resistant mantle cell lymphoma. Haematologica. 2022; 108(6):1616-1627. PMC: 10230437. DOI: 10.3324/haematol.2022.281538. View

19.

Kale J, Osterlund E, Andrews D . BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 2017; 25(1):65-80. PMC: 5729540. DOI: 10.1038/cdd.2017.186. View

20.

Thus Y, Eldering E, Kater A, Spaargaren M . Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma. Leukemia. 2022; 36(9):2165-2176. PMC: 9418002. DOI: 10.1038/s41375-022-01627-9. View